Bionest

Applying Precision Medicine to Neuropsychiatric Disorders

Cancers were once looked upon as specific diseases, often defined by their tissue of origin, and drug treatments primarily aimed to kill rapidly growing tumor cells before harming slower growing normal ones. The result was often limited drug efficacy, accompanied by debilitating side-effects. Today, however, the growing understanding of the biology and genetics of particular...

Bionest

Highlights from AAN: Part 2

We continue our report of interesting developments from the American Academy of Neurology meeting:   Neuromyelytis Optica Spectrum Disorder (NMOSD)   Interest in a rare disease called neuromyelytis optica spectrum disorder (NMOSD) appears to be growing. NMOSD is an autoimmune condition that causes swelling of the optic nerve and spinal cord, which can result in...

Bionest

Highlights from AAN: Part 1

The Bionest team attended the American Academy of Neurology (AAN) in early May, where we heard exciting data presented in a number of neurological conditions. Among the highlights of this year’s conference:   Transformative Success in Spinal Muscular Atrophy   Spinal muscular atrophy (SMA) was a hot topic at AAN, with presentations of positive clinical...